We treated 5 melanoma cell lines (2 NRASQ61 mutant: DO4, MM415; 3 patients derived BRAFV600E mutant: AV1, AV4, AV5) with increasing dosages of the MEK inhibitor trametinib and the BRAF inhibitor PLX4720. This evidence concerns the gene MAP2K7 and melanoma.